What is Ait Bioscience?
Ait Bioscience operates as a specialized contract research laboratory, providing comprehensive analytical solutions that span the entire drug development lifecycle. From pre-clinical stages through Phase I-III clinical trials, the firm utilizes a sophisticated smart electronic laboratory environment to deliver high-fidelity data. Their core competencies include Ligand Binding Assay (LBA) analytics for large molecules and LC-MS/MS analytics for small and large molecules. By integrating these analytical methods with efficient sample logistics and expert consultation, Ait Bioscience serves as a vital partner for organizations navigating the rigorous requirements of IND and NDA submissions.
How much funding has Ait Bioscience raised?
Ait Bioscience has raised a total of $1.4M across 2 funding rounds:
Private Equity
$1M
Debt
$350K
Private Equity (2013): $1M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Key Investors in Ait Bioscience
PPP
Public-Private Partnership
Undisclosed Private Equity
A private equity firm focused on long-term capital appreciation within the life sciences and contract research services sector.
N/A
Undisclosed investor participating in the funding round.
What's next for Ait Bioscience?
With the recent influx of capital, Ait Bioscience is poised to scale its operational capacity and further refine its proprietary analytical methodologies. The strategic focus will likely center on expanding its footprint in the competitive contract research organization (CRO) landscape, particularly by enhancing its digital laboratory infrastructure to meet the evolving needs of modern drug discovery. As the firm moves forward, the emphasis will remain on maintaining the robust quality control processes that have become its hallmark, while simultaneously exploring new technological frontiers in bioanalytical science to support the next generation of therapeutic breakthroughs.
See full Ait Bioscience company page
